MA34646B1 - Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17 - Google Patents

Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17

Info

Publication number
MA34646B1
MA34646B1 MA35872A MA35872A MA34646B1 MA 34646 B1 MA34646 B1 MA 34646B1 MA 35872 A MA35872 A MA 35872A MA 35872 A MA35872 A MA 35872A MA 34646 B1 MA34646 B1 MA 34646B1
Authority
MA
Morocco
Prior art keywords
antagonists
methods
treating psoriasis
antibody
binding molecule
Prior art date
Application number
MA35872A
Other languages
English (en)
Inventor
Achim Guettner
Matthias Machacek
Charis Papavassilis
Oliver Sander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34646(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34646B1 publication Critical patent/MA34646B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux régimes pour le traitement du psoriasis, qui utilisent une quantité thérapeutiquement efficace d'un antagoniste de IL-17, tel qu'une molécule de liaison à IL-17, par exemple un anticorps de IL-17 (tel que l'anticorps secukinumab), ou une molécule de liaison à un récepteur de IL-17, par exemple un anticorps du récepteur de IL-17.
MA35872A 2010-10-08 2013-05-03 Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17 MA34646B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (fr) 2010-10-08 2011-10-07 Méthodes de traitement du psoriasis au moyen d'antagonistes de il-17

Publications (1)

Publication Number Publication Date
MA34646B1 true MA34646B1 (fr) 2013-11-02

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35872A MA34646B1 (fr) 2010-10-08 2013-05-03 Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17

Country Status (27)

Country Link
US (6) US9717791B2 (fr)
EP (4) EP3792281A1 (fr)
JP (2) JP5537740B2 (fr)
KR (3) KR20150018595A (fr)
CN (2) CN107029234A (fr)
AU (1) AU2011311482B2 (fr)
BR (1) BR112013008501A2 (fr)
CA (1) CA2813900C (fr)
CL (1) CL2013000930A1 (fr)
CY (1) CY1119942T1 (fr)
DK (1) DK2625199T3 (fr)
ES (1) ES2660770T3 (fr)
HK (1) HK1247932A1 (fr)
HR (1) HRP20180301T1 (fr)
HU (1) HUE038334T2 (fr)
IL (1) IL225310A (fr)
LT (1) LT2625199T (fr)
MA (1) MA34646B1 (fr)
MX (1) MX356279B (fr)
NO (1) NO2625199T3 (fr)
PL (1) PL2625199T3 (fr)
PT (1) PT2625199T (fr)
RU (2) RU2665954C1 (fr)
SG (1) SG188979A1 (fr)
SI (1) SI2625199T1 (fr)
TW (2) TWI564022B (fr)
WO (1) WO2012045848A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011088120A1 (fr) 2010-01-15 2011-07-21 Amgen Inc. Formulation d'anticorps et régimes thérapeutiques
BR112012029588A2 (pt) 2010-05-20 2017-07-25 Ablynx Nv materiais biológicas relacionados a her3.
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
KR20140097178A (ko) * 2011-11-21 2014-08-06 노파르티스 아게 IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법
JP2016517408A (ja) * 2013-03-15 2016-06-16 アムジェン インコーポレイテッド 抗ｉｌ−２３抗体を用いた乾癬の治療方法
AU2014228553B2 (en) * 2013-03-15 2019-01-24 Amgen Inc. Methods for treating Crohn's disease using an anti-IL23 antibody
US10434172B2 (en) * 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
WO2015099167A1 (fr) * 2013-12-27 2015-07-02 国立大学法人大阪大学 Vaccin ciblant l'il-17a
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
US20170174772A1 (en) * 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10039810B2 (en) 2014-05-15 2018-08-07 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies
AU2015307868B2 (en) * 2014-08-26 2020-08-27 Amgen K-A, Inc. Method for treating psoriasis patient which received anti-TNF-alpha antibody therapy
WO2016038538A1 (fr) * 2014-09-10 2016-03-17 Novartis Ag Utilisation d'antagonistes d'il-17 pour inhiber la progression d'une lésion structurelle chez des patients atteints d'une polyarthrite psoriasique
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2978449A1 (fr) 2015-03-02 2016-09-09 180 Therapeutics Lp Methode de traitement d'un trouble fibrotique localise a l'aide d'un antagoniste de l'il-33
EP3167892A1 (fr) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour la prévention ou le traitement de maladies intestinales inflammatoires
WO2017072183A1 (fr) * 2015-10-27 2017-05-04 Ucb Biopharma Sprl Méthodes de traitement à l'aide d'anticorps anti-il-17a/f
JP2019521156A (ja) * 2016-07-19 2019-07-25 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (fr) * 2017-03-03 2018-09-07 Novartis Ag Modification de la maladie du psoriasis suite à un traitement à long terme avec un antagoniste de l'il-17
EP3672988A1 (fr) * 2017-08-23 2020-07-01 Eli Lilly and Company Traitement du psoriasis génital
TWI725532B (zh) * 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
WO2023186174A1 (fr) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Formulation topique comprenant une molécule de liaison à l'il-17 et ses utilisations
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TW201705980A (zh) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1933869B1 (fr) * 2005-09-01 2009-10-14 Schering Corporation Utilisation d'antagonistes de l'il-23 et de l'il-17 pour le traitement de la maladie inflammatoire oculaire auto-immune
EP3366702B1 (fr) * 2005-12-13 2023-08-09 Eli Lilly And Company Anticorps anti-il-17
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
WO2008150490A2 (fr) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Compositions et utilisations pour le traitement du psoriasis et de la maladie de crohn
RU2341272C1 (ru) * 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
CN102617735B (zh) * 2008-09-29 2015-09-09 罗氏格黎卡特股份公司 针对人il17的抗体及其应用

Also Published As

Publication number Publication date
BR112013008501A2 (pt) 2016-08-16
ES2660770T3 (es) 2018-03-26
HUE038334T2 (hu) 2018-10-29
EP4137514A1 (fr) 2023-02-22
CN103154031A (zh) 2013-06-12
US20200171147A1 (en) 2020-06-04
CN107029234A (zh) 2017-08-11
MX2013003916A (es) 2013-06-03
WO2012045848A1 (fr) 2012-04-12
PT2625199T (pt) 2018-02-28
RU2013120957A (ru) 2014-11-20
US20130202610A1 (en) 2013-08-08
MX356279B (es) 2018-05-22
EP3299390A1 (fr) 2018-03-28
SG188979A1 (en) 2013-05-31
EP2625199B1 (fr) 2017-11-22
AU2011311482A1 (en) 2013-04-04
AU2011311482B2 (en) 2014-05-29
TW201216984A (en) 2012-05-01
TW201630625A (zh) 2016-09-01
CA2813900C (fr) 2017-01-10
IL225310A (en) 2016-10-31
US20210162044A1 (en) 2021-06-03
US9717791B2 (en) 2017-08-01
KR20140097566A (ko) 2014-08-06
HK1247932A1 (zh) 2018-10-05
KR20150018595A (ko) 2015-02-23
NO2625199T3 (fr) 2018-04-21
US20170304439A1 (en) 2017-10-26
US20210113688A1 (en) 2021-04-22
DK2625199T3 (en) 2018-02-26
TWI564022B (zh) 2017-01-01
PL2625199T3 (pl) 2018-04-30
CL2013000930A1 (es) 2014-03-28
JP5537740B2 (ja) 2014-07-02
EP3792281A1 (fr) 2021-03-17
TWI548419B (zh) 2016-09-11
LT2625199T (lt) 2018-03-12
US10583190B2 (en) 2020-03-10
JP2013543501A (ja) 2013-12-05
KR101620771B1 (ko) 2016-05-12
IL225310A0 (en) 2013-06-27
RU2665954C1 (ru) 2018-09-05
RU2591083C2 (ru) 2016-07-10
CA2813900A1 (fr) 2012-04-12
JP2014114288A (ja) 2014-06-26
US11534490B2 (en) 2022-12-27
EP2625199A1 (fr) 2013-08-14
SI2625199T1 (en) 2018-03-30
US20230321231A1 (en) 2023-10-12
HRP20180301T1 (hr) 2018-03-23
CY1119942T1 (el) 2018-12-12
KR20130110179A (ko) 2013-10-08

Similar Documents

Publication Publication Date Title
MA34646B1 (fr) Procedes de traitement du psoriasis en utilisant des antagonistes d'il-17
MA34647B1 (fr) Procedes de traitement de la polyarthriterhumatoide en utilisant des antagonistes dil-17
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
NO20065252L (no) Behandling av forstyrrelser
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
ATE464305T1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
MA29330B1 (fr) Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires.
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
MA35404B1 (fr) Composés pour le traitement de la toxicomanie
ATE537170T1 (de) Cgrp-rezeptorantagonisten
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ATE537153T1 (de) Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
DE602008005771D1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
ATE411323T1 (de) Cgrp-rezeptorantagonisten